Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Cardiac Catheterization IV: Nursing Management01:26

Cardiac Catheterization IV: Nursing Management

Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intermediate-dose anticoagulation in COVID-19: closing the loop on a long-settled question.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Fatal Pulmonary Embolism in Professional Athletes: A Window Into a Broader VTE Problem.

Journal of the American College of Cardiology·2026
Same author

Advanced Therapy for Intermediate-Risk Pulmonary Embolism.

The New England journal of medicine·2026
Same author

Surgical and procedural bleed risk stratification for anticoagulated patients undergoing planned surgery: guidance from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Bleeding risk prediction models in varied clinical scenarios.

Journal of thrombosis and haemostasis : JTH·2026
Same author

"Perioperative management of direct oral anticoagulants in patients having a high-bleed-risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation 2 pilot randomized trial": reply.

Journal of thrombosis and haemostasis : JTH·2025

Related Experiment Videos

Oral anticoagulation: preparing for change.

Edith A Nutescu1, Alex C Spyropoulos, Kerry W Cranmer

  • 1University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA.

Journal of the American Medical Directors Association
|October 24, 2007
PubMed
Summary

New oral anticoagulants like ximelagatran offer alternatives to warfarin for preventing stroke and venous thromboembolism (VTE). Ximelagatran, a direct thrombin inhibitor, shows promise with convenient dosing and fewer drug interactions.

Related Experiment Videos

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Thrombosis Research

Background:

  • Thromboembolic disorders, including stroke and venous thromboembolism (VTE), are significant causes of mortality and morbidity.
  • The aging population, particularly baby boomers, will increase the prevalence of patients at risk for these conditions.
  • Current long-term prophylactic therapy with oral warfarin faces challenges, including dose monitoring, side effects, and drug interactions, necessitating alternative treatments.

Purpose of the Study:

  • To evaluate the efficacy and safety of ximelagatran as a novel oral anticoagulant for preventing thromboembolic disorders.
  • To compare ximelagatran with warfarin, the current standard of care, in a large patient population.

Main Methods:

  • Phase III clinical trials were conducted to assess ximelagatran's effectiveness and tolerability.
  • Ximelagatran, an oral direct thrombin inhibitor, was administered twice daily.
  • Study endpoints included the prevention of stroke and VTE, with safety monitoring for adverse events like liver enzyme elevations.

Main Results:

  • Clinical trial results suggest ximelagatran may be as effective as warfarin in preventing stroke and VTE.
  • Ximelagatran offers a favorable pharmacokinetic profile with potential for reduced drug interactions and a wide therapeutic window.
  • Liver enzyme elevations were observed in clinical trials, representing an unresolved safety concern.

Conclusions:

  • Ximelagatran presents a promising alternative oral anticoagulant for long-term prophylaxis against stroke and VTE.
  • Its convenient administration and potentially reduced monitoring requirements could improve patient adherence and optimize therapy.
  • Further investigation into the safety profile, particularly concerning liver enzyme elevations, is warranted.